Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$445.00K$445.00Kderived−25.5% vs Q4 2022 Net Income-$18.92M-$18.92MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$15,142,000N/M Operating Cash Flowderived-$16,958,000N/M Margins · derivedOperating margin-3402.7%−357.8 pt vs Q4 2022
Net margin-4251.5%+488.6 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 5, 2024 · 65 d after period end